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Tumor necrosis factor-alpha (TNF-α), an established pro-inflammatory cytokine plays
a central role in the induction and progression of several chronic inflammatory and
autoimmune diseases. Targeting TNF-α as a treatment modality has shown tremendous
success, however there are several limitations associated with the current anti-TNF-
α biologic drugs including: immunogenicity, life-threatening infections, resistance to
treatment, complexity of manufacture and cost of treatment. Here, we report the in
vivo efficacy of novel anti-TNF-α formats generated from molecular engineering of
variable new antigen receptors (VNARs), originally derived from the immune system of an
immunized nurse shark. Two anti-TNF-α VNAR formats, a tandem multivalent trimer, D1-
BA11-C4 and an Fc-fused quadrivalent D1-Fc-C4 (Quad-XTM) construct were tested in a
clinically relevant, preclinical mouse efficacy model of polyarthritis (Tg197) and compared
to the commercial anti-TNF-α “best in class” therapy, Adalimumab (Humira®). Both VNAR
formats bind and neutralize TNF-α through an epitope that appears to be different from
those recognized by other anti-TNF biologics used clinically. All doses of Quad-XTM, from
0.5 to 30 mg/kg, significantly blocked the development of polyarthritis. At 0.5 mg/kg
Quad-XTM, the arthritis score was improved by 76% and the histopathology score by
63%. At 3 mg/kg Quad-XTM, control of disease was almost complete at 90% (arthritis)
and 88% (histopathology). In marked contrast, 1 mg/kg Humira® saw profound disease
breakthrough with scores of 39 and 16% respectively, increasing to a respectable 82 and
86% inhibition at 10 mg/kg Humira®. We have previously reported the superior potency
of anti-TNF-α VNARs in vitro and in these studies translate this superiority into an in
vivo setting and demonstrate the potential of VNAR formats to meet the requirements of
next-generation anti-TNF-α therapies.
Keywords: variable new antigen receptors (VNARs), TNF-alpha, autoimmune disease, rheumatoid arthritis,
anti-TNF biologics, shark IgNAR, chronic inflammation
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INTRODUCTION
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine
with beneficial functions in immune regulation and host defense,
but when expressed at high levels, is also implicated in a
number of human diseases. TNF-α is a critical mediator of the
autoimmune process, playing a key role in several inflammatory
diseases ranging from rheumatoid arthritis, inflammatory bowel
diseases, psoriasis, and uveitis. Rheumatoid arthritis (RA) is a
common, chronic inflammatory disorder that causes progressive
articular destruction and is associated with comorbidities in
vascular, metabolic, bone and even the psychological well-being
of sufferers (1, 2). Affecting about 1% of the global population, RA
patients are faced with functional disability, pain, joint damage,
a reduced quality of life, and even premature mortality, with
a corresponding and significant negative economic impact on
both the patients and government health systems struggling to
treat the disease (3, 4). The management of many autoimmune
mediated diseases has significantly improved in the last decade
because a better understanding of disease mechanisms has
guided the development of new and potent therapies. The
mainstay treatment for steroid-refractory RA is via the targeted
neutralization/blocking of the TNF-α signaling pathway with
anti-TNF-α or anti-TNF receptor biologics. The monoclonal
antibody, Adalimumab (Humira R©) is the most widely used and
commercially successful TNF-α antagonist monoclonal antibody
(5–7). However, there still remain some significant limitations
with this treatment approach. Approximately 50% of patients fail
to see their disease properly controlled with the existing battery
of anti-TNF biologics. A failure to respond to treatment or the
development of resistance to therapy (through immunogenicity
or other mechanisms), the use of progressively higher doses (10–
30 mg/kg) with prolonged therapy windows, concomitant, and
often significant systemic side-effects (infection, heart problems,
malignancy) are just few of the limitations associated with the
current anti-TNF biologics in the clinic (8–16). Some of these
limitations are in part also related to the molecular mass and
structural complexity of mAbs which can increase manufacturing
costs and clinically limit routes of administration.
The Variable New Antigen Receptors (VNARs) are the
smallest (11 kDa) naturally occurring independent binding
domains in the vertebrate kingdom (17–19). They play an integral
role in the adaptive immune system in cartilaginous fish and
although they are structurally similar to mammalian heavy and
light variable chains it has been well-documented that they arose
from a distinct evolutionary lineage from Immunoglobulins (20).
A lack of CDR2 and the addition of two loops of diversity
(HV2 and 4) as well as low percentage sequence homology
exemplifies this distinction. Their characteristic protruding
paratopes, often referred to as “canyon-binders,” predisposes
these domains to access and bind epitopes not normally available
to conventional biologics and encourages the selection of
highly potent neutralizers specific for enzyme and/or receptor
targets (21–23). We have previously demonstrated the ease
with which reformatting of VNAR domains can be achieved
delivering: multivalent, bi/tri-specific constructs, and serum
half-life extension through molecular fusion to an anti-human
serum albumin (HSA) VNAR scaffold, NDureTM or via a more
traditional route using IgG (mouse or human) Fc domains
(24–26). These highly stable constructs can be expressed cost-
efficiently and at scale in non-mammalian systems. This menu
of format options permits tailored selection of drug modalities
optimized for systemic, site-specific, or topical administration of
VNAR candidates.
Here, we have demonstrated that an anti-hTNF-α VNAR
construct (Quad-XTM) previously reported as having potent in
vitro activity (24) retains this superiority to the commercially
available blockbuster anti-TNF-α, Adalimumab (Humira R©) in
vivo and is capable of preventing the development of spontaneous
polyarthritis in a transgenic mouse model of arthritis at doses
below 3 mg/kg. Also, and for the first time, we have shown
that sustained in vivo efficacy is possible from a non-Fc fused
anti-HSA half-life extended linear VNAR construct following
systemic administration in the same RA disease model.
MATERIALS AND METHODS
Anti-hTNF-α VNAR Domain Reformatting,
Expression and Purification
The rational design and reformatting of the two anti-hTNF-
α VNAR test articles (D1-BA11-C4 and D1-Fc-C4 (Quad-XTM)
has been described in a recent publication (24). D1-BA11-C4
is a 40 kDa trivalent, bi-specific, bi-paratopic VNAR construct
targeting hTNF-α via the D1 and C4 domains molecularly fused
with a validated, clinical-study ready, serum half-life extension
humanized VNAR (soloMERTM) domain, BA11 (NDureTM)
targeting serum albumin (Figure 1). The VNAR domains in
the trimer construct are separated by flexible (Gly4Ser)4 linkers
and contain a C-terminally fused 6x Histidine tag to facilitate
purification. The Quad-XTM construct (Figure 1), a 105 kDa
fusion molecule was designed with two varying GlySer linker
lengths; a short (Gly4Ser)2 fusing the first anti-hTNF-α VNAR
domain (D1) to the hinge of a wild-type human IgG1 Fc
region, and a longer (Gly4Ser)4 linker fused to the C-terminal
of an Fc CH-3 linking to a second anti-hTNF-α VNAR domain
(C4). Purification of this construct is via the human IgG1 Fc,
using Protein-A affinity chromatography. Both constructs were
expressed in suspension-adapted CHO K1 cells.
Cross-Reactivity Binding ELISA and
Cytokine Neutralization Assay
ELISA plates were coated with human, mouse, rat, dog,
cynomolgus, rabbit, pig TNF-α and human TNF-β at 1µg/ml
concentration in PBS. Plates were incubated for 1 h at 37◦C,
then blocked with 2%Milk-PBS. Plates were washed 3x with PBS
and 0.001% (v/v) Tween-PBS (PBST). Anti-TNF-α VNAR D1
and C4, VHH TNF30 and Humira R© were added to designated
ELISA wells at a 5µg/ml top concentration with 2-fold serial
dilution. Plates were incubated at room temperature for 1 h,
washed as described above. TNF-α binding activity was detected
using appropriate secondary antibodies; VNARs D1 and C4, and
VHH TNF30 were detected using anti-poly-histidine-HRP, and
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FIGURE 1 | Schematic ribbon illustration, analytical SEC and SDS-PAGE profile of purified VNAR test articles. (A) SEC traces are shown as overlaid and offset to aid
comparison. The chromatograms confirm no evidence of aggregation or impurities in the samples. Red trace—D1-BA11-C4, Blue trace—Quad-XTM. (B) SDS-PAGE
and Coomassie blue staining of 5 µg of dithiothreitol-treated VNAR constructs. M, molecular weight marker; Lane 1, VNAR D1-BA11-C4; Lane 2, VNAR-Fc standard
control (≈ 45 kDa); Lane 3, D1-Fc-C4 (Quad-XTM) Ubah et al. (24).
Humira R© was detected using an HRP-conjugated anti-human
IgG1 Fc antibody.
An in vitro TNF-α neutralization assay in a mouse
fibrosarcoma (L929) cell line was conducted as described in
Ubah et al. (24). LD50 doses for the TNF-α species, as
determined through cytokine titration in the same L929 cells
cytotoxicity assay, are as follows; human TNF-α (0.3 ng/ml),
mouse TNFα (0.05 ng/ml), cynomolgus TNF-α (0.15 ng/ml), pig
TNF-α (100 ng/ml), canine TNF-α (0.5 ng/ml), and human TNF-
β (0.5 ng/ml). A neutralization screen was not performed when
all the test anti-TNF-α domains (VNARs, VHH and Humira R©)
failed to bind a target species TNF-α, e.g., rat and rabbit TNF-α.
Analytical SEC & SDS-PAGE Profile of
Recombinant Anti-hTNF-α VNAR Domains
Aggregation propensity of the reformatted VNAR test articles
was analyzed using analytical size-exclusion chromatography
(SEC) and an Agilent 1200 series HPLC system with a ZORBAX
GF 250 9.4 × 250mm 4µm column containing phosphate
buffered saline pH 7.4 as the mobile phase. VNAR D1-BA11-
C4 and Quad-XTM were loaded onto columns at 6 mg/ml from
stock concentrations of 40 mg/ml. Purity of the test VNAR
protein samples was also assessed by SDS-PAGE electrophoresis
of the reduced VNAR protein samples in a MES buffer
system (Invitrogen).
Mice
C57BL/6 and Tg197 mice were used for the maximum tolerated
dose (MTD) and polyarthritis prevention studies, respectively
and were provided by Biomedcode Hellas SA, Greece. All
reported animal studies were conducted at the Biomedcode
SA test facility. All procedures conformed to the Presidential
Decree No 56/2013 Government Gazette No A’ 106 applicable in
Greece (EEC Directive 2010/63/ECC) and were approved by the
directorate of Agricultural and Veterinary Policy (DAVP) of the
Attica Region. Approved license Protocol No. 3798/3-07-2017.
Treatments
Anti-humanTNF-αVNARs, D1-BA11-C4 andD1-Fc-C4 (Quad-
XTM) were produced recombinantly in suspension-adapted
CHO K1 cells by Evitria AG, Switzerland. In vitro functional
activity of these expressed proteins was confirmed (24), and
“safe” endotoxin levels determined using a PierceTM LAL
Chromogenic Endotoxin Quantitation Kit (Product no. 88282)
(Data not shown). Humira R©, a gold standard anti-hTNF-α
human monoclonal antibody (human IgG1 Fc) was locally
purchased by Biomedcode SA (Lot/batchNo. 74270XH07, Expiry
date 01/2019). D-PBS was used as the stock solution diluent and
the vehicle control was again purchased locally by Biomedcode
SA (Lot/batch no. 1892388, expiry date 06/2020).
Maximum Tolerated Dose (MTD) in
C57BL/6 Mice
Anti-hTNF-α Quad-XTM was evaluated for safety and tolerability
in healthy mice. A pool of 6-week-old C57BL/6 mice were
allocated to 4 groups (G1-G4), each consisting of 10 gender and
age matched mice, based on an equal mean group body weight
distribution. On days 0 and 3, animals received subcutaneous
administration of either vehicle (PBS, G1), 3 mg/kg (G2), 10
mg/kg (G3), or 30 mg/kg (G4) of anti-hTNF-α Quad-XTM.
Treated animals were monitored daily for 7 consecutive days to
assess any possible adverse effects by recording animal viability,
overall appearance, body function, behavior, and body weight.
Water and food intake were also assessed at 2 different time
points during the study. At the end of the clinical monitoring
period, mice were sacrificed, and gross necropsy determined.
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The heart, liver, spleen and kidneys from all experimental
animals were collected and weighed to determine organ to body
weight ratios.
Polyarthritis Prevention in the Tg197
Mouse Model
The transgenic Tg197 mouse model was used to investigate the
efficacy of the anti-hTNF-α VNAR D1-BA11-C4 and Quad-XTM
formats and compared to the positive control article Humira R©,
as described in Keffer et al. (27). The Tg197 mice carry a
human TNF transgene, which has been modified to include
a 3
′
-untranslated region sequence from a beta-globin gene,
thereby allowing deregulated human TNF gene expression. In
mice containing this genetic background, chronic polyarthritis
incidence is 100% by week 4 of age. In this therapeutic
model, treatment is aimed at preventing establishment of
disease by blocking the biological activity of the deregulated
hTNF-α expression.
This study was conducted using two independent
experiments. In the first, 5 groups of 8 sex and age matched mice
(4♂/4♀) were assigned to one of five treatment regimens. PBS
treatment, three different dosing regimens of VNAR Quad-XTM
and one dosing regimen of Humira R©. Doses of 3, 10, 30 mg/kg
(Quad-XTM), and 10 mg/kg (Humira R©) were administered
subcutaneously twice weekly, starting at week 3 after birth until
10 weeks of age.
In the second study, 7 groups of 8 mice each (4♂/4♀) were
assigned to one of seven treatments regimens of twice weekly
subcutaneous administration. VNARQuad-XTM was dosed at 0.5,
1, and 3 mg/kg; VNAR D1-BA11-C4 at 30 mg/kg; and Humira R©
at 1 and 3 mg/kg.
An additional group of untreated mice for baseline
histopathological status (3-week-old control mice) were
sacrificed prior to the first dose administration. An in
vivo arthritis scoring system (28) was applied based on the
macroscopic changes observed in joint morphology on both
ankle joints of the hind limbs. An arthritis score (AS) was
recorded weekly on both ankle joints, and average scores were
calculated. All mice were sacrificed 48 h after administration
of the last dose (week 10 of age), and two ankle joints of each
animal were collected for histopathological evaluation.
Histopathological Evaluation
Ankle joints were fixed in 4% aqueous formaldehyde solution
overnight at room temperature, demineralised in EDTA
decalcification solution (13% EDTA in 0.1M sodium phosphate
buffer) at room temperature for 30 days and placed in
PBS at 4◦C until required for further processing. Samples
were paraffin embedded in the sagittal plane, and paraffin
blocks sectioned. Blocks were stained with Haematoxylin and
Eosin (H&E) staining and evaluated by light microscopy for
histopathological hallmarks of arthritis in accordance with a
standard histopathology scoring system (29, 30). The evaluation
process was performed in a blinded fashion based only on a slide
number and not the sample ID. Only representative images were
acquired (25x magnification), and group means were calculated
from the individual highest scores per joint in eachmouse in each
specific group.
Preclinical Study Amendments
and Deviations
In the MTD study, during the necropsy procedure and organ
collection weighing, the right kidneys of two mice (one in
10 mg/kg Quad-XTM and the other in the 30 mg/kg Quad-
XTM treatment group) were not recovered, therefore no weight
of the right kidney was recorded. There were no other study
amendments or deviations, and no deaths were reported in both
the MTD and Efficacy Preclinical studies.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6
software. Statistical tests applied to each data set are specified in
each figure legend. Statistically significant differences were noted
as: ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001, ∗∗∗∗p< 0.0001.
RESULTS
SEC & SDS-PAGE Analysis of VNAR
Test Articles
VNAR test articles were expressed, purified and assessed for
function in both binding ELISA and classical L929 fibrosarcoma
cells—hTNF-α neutralization assay (24). Analytical SEC was
performed to determine the presence of any aggregation in
concentrated (40 mg/ml) reformatted VNAR protein samples
prior to their in vivo use. Both VNAR D1-BA11-C4 and Quad-
XTM eluted as single peaks and showed no signs of aggregation
or impurities. In addition, SDS-PAGE analysis of 5 µg VNAR
D1-BA11-C4 and Quad-XTM confirmed the SEC analysis with no
evidence of degradation or impurities observed (Figures 1A,B).
Species Cross-Reactivity Characterization
of Lead Anti-TNF VNAR Domains
The lead individual anti-TNF-α VNAR domains (D1 and
C4) showed positive reactivity to only human, dog and
cynomolgus TNF-α. There was no binding seen with any of
these VNAR domains to rat, mouse, rabbit, pig TNF-α or closely
related human TNF-β (Table 1A). These binding recognition
and neutralization profiles clearly separated these two VNAR
binding domains from the profile seen with Humira R© and the
VHH TNF30. Humira R© binds and neutralizes human, dog,
cynomolgus and mouse TNF-α, while VHH TNF30, in addition
to binding and neutralizing human, dog, cynomolgus and pig
TNF-α, binds human TNF-β.
Clinically available anti-TNF-α therapies including Infliximab
(Remicade R©) a mouse-human IgG1-kappa, Certolizumab
(Cimzia R©) a PEGylated Fab fragment of a humanized mAb,
Golimumab (Simponi R©) a fully human IgG1-kappa mAb, and
Etanercept (Enbrel R©) a fusion protein of human TNF receptor 2,
all show restricted TNF-species cross-reactivity with recognition
profiles different from those determined for the anti-TNF-α
VNARs. Infliximab binds and neutralizes only human TNF-α
and chimpanzee; Etanercept binds and neutralizes human,
cynomolgus, mouse TNF-α and human TNF-β; Certolizumab
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TABLE 1 | Cross-reactivity profile of anti-hTNF-alpha VNAR lead constructs compared to commercially available anti-hTNF-alpha mAbs and a pre-clinical VHH TNF30
domain.
(A). Binding (B) and Neutralization (N) data obtained in our laboratory.
Human
(bind/neutralize)
B/N
Dog
(B/N)
Cynomolgus
(B/N)
Rat
(B/N)
Mouse
(B/N)
Rabbit
(B/N)
Pig
(B/N)
Human
TNF-β
(B/N)
Lead anti-hTNF-α VNARs (D1 & C4) +++/+++ +++/+++ +++/+++ –/– –/– –/– –/– –/–
TNF30
(VHH)
+++/+++ +++/+++ +++/+++ –/– –/– –/– +/+ ++/–
Adalimumab
(Humira®)
+++/+++ +++/+++ +++/+++ –/– ++/++ –/– –/– –/–
+ + + denotes strong binding/neutralization activity, ++ moderate; + very weak activity and—denotes no binding/neutralization activity observed. Binding (B) and Neutralization (N).
TNF30 is an anti-TNF-α Nanobody
TM
previously reported in Beirnaert (31).
binds and neutralizes human and cynomolgus TNF-α, and
Golimumab binds and neutralizes human, dog, cynomolgus, and
rabbit TNF-α (Table 1B) (32–34).
In vivo Preclinical Safety of Quad-XTM
VNAR multivalent tandem and VNAR-Fc constructs have
previously been successfully administered in several animal
models including non-human primates, with no drug-associated
toxicities reported (25, 26). However, this is the first time a
Quad-XTM format (24) has been tested in an animal model and
therefore, an indication of the maximum tolerated dose (MTD)
in healthy mice was sought. C57BL/6 mice were treated with
increasing doses of D1-Fc-C4 (Quad-XTM) up to a maximum
dose of 30 mg/kg administered subcutaneously and dosed twice
within a week. Thesemice weremonitored daily for 7 consecutive
days for possible signs of any adverse treatment effects by
recording animal viability, overall appearance, body function,
behavior, body weight, water, and food intake. There were no
observed adverse effects during the daily clinical observations
and no significant body or organ weight changes observed
between the control (PBS) and Quad-XTM treatment groups
(Figure 2A). Food and water intake remained unchanged in
the treatment groups compared to the untreated control group
(data not shown). Following necropsy examinations, organs
were found to be normal in colour, size, and consistency while
cavities were clean with no signs of pathology. The ratio of the
organ weights to body weights did not show any significant
differences between different treatment groups (Figure 2B).
The organ to body weight ratio is an assessment of possible
abnormality and is indicative of a putative toxic effect of
the test article.
Efficacy of D1-BA11-C4 and Quad-XTM in
Preventing Arthritis in Tg197 Mice
Anti-hTNF-α VNAR constructs, D1-BA11-C4 and D1-Fc-C4
(Quad-XTM) which are potent (low pM) in vitro neutralizers of
hTNF-α (24) were tested in the Tg197 transgenic human TNF-
α model of polyarthritis, in which mice constitutively produce
the pro-inflammatory human TNF-α cytokine, and consequently
develop spontaneous arthritis. Two independent studies were
conducted as described in Polyarthritis prevention in the Tg197
mouse model. In the first study, a standard preclinical dosing
regimen of 3, 10, and 30 mg/kg was adopted as dosing at
these levels has been well reported in this model (33, 35, 36).
In the second study, the dosing regimen of our anti-hTNF-
α constructs was titrated down to only 0.5, 1, and 3 mg/kg
(study 1 showed complete disease control and no dose-dependent
response, see below for details) vs. 1 and 3 mg/kg Humira R©.
For the first time in a clinically relevant animal model, a non-Fc
based VNAR trimer construct (D1-BA11-C4) was administered
parenterally at 30 mg/kg twice weekly for the duration
of the study.
After 14 doses administered twice weekly for a period of 7
weeks, the results of the first study showed that all doses of Quad-
XTM and D1-BA11-C4 at 30 mg/kg (second study) blocked the
development of disease and sustained increase in body weight
(Figures 3, 4, 5). In vivo arthritis and histopathology scores
were inhibited by an average 88% and 86% respectively, across
all anti-hTNF-α VNAR doses tested, with 0.5 mg/kg Quad-XTM
inhibiting in vivo arthritis and histopathology scores at 76%
(p = 0.0001) and 63% (p < 0.0002), 88% (p < 0.0001) and 85%
(p< 0.0001) with 1 mg/kg Quad-XTM, and 90% (p< 0.0001) and
88% (p < 0.0001) inhibition respectively with 3 mg/kg Quad-
XTM. Humira R© inhibited arthritis and histopathology scores by
an average of 84 and 76%, respectively at the 3 & 10 mg/kg
dosing regimens, and the disease score inhibition at 1 mg/kg
Humira R© saw significant breakthrough of disease with values
of only 39% (p = 0.923) and 16% (p = 0.999) for in vivo
arthritis and histopathology scores, respectively. D1-BA11-C4 at
30 mg/kg dosing inhibited in vivo arthritis and histopathology
scores by 90% (p < 0.0001) and 89% (p < 0.0001) respectively.
The comparative examination of the arthritis inhibitory effects
of Quad-XTM and Humira R© at 1 mg/kg and 3 mg/kg dose level
revealed that they were statistically undifferentiated in terms of
their body weight gain measurement, but the in vivo arthritic and
histopathological evaluations revealed that Quad-XTM displayed,
with statistical significance, superior efficacy to Humira R©. By,
the end of study (week 10 of age) mean body weight for the 1
mg/kg Humira R© treated mice group was 19.9 ± 0.9 g compared
to 17.7 ± 1.3 g (PBS treated group) (p = 0.768). Mean body
weight in the 0.5 mg/kg and 1 mg/kg treated groups were 22.5
± 1.6 g (p = 0.093) and 23.9 ± 1.3 g (p = 0.017) respectively.
The average body weight of a healthy 10-week-old mouse is ≈
25 g (male) and 20 g (female). The study 3-week-old control mice,
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TABLE 1B | Additional cross-reactivity information reported in a published assessment report§.
Human
(bind/neutralize)
B/N
Dog
(B/N)
Cynomolgus
(B/N)
Rat
(B/N)
Mouse
(B/N)
Rabbit
(B/N)
Pig
(B/N)
Human
TNF-β
(B/N)
Adalimumab
(Humira®)
+/+ +/+ +/+ –/– +/+ –/– –/– –/–
Infliximab
(Remicade® )
+/+ –/– –/– –/– –/– –/– –/– –/–
Etanercept
(Enbrel® )
+/+ –/– +/+ n/a +/+ n/a n/a +/+
Certolizumab
(Cimzia®)
+/+ –/– +/+ n/a n/a n/a n/a n/a
Golimumab
(Simponi® )
+/+ +/+ +/+ –/– –/– +/+ n/a –/–
§ European Medicines Agency Evaluation of Medicines for Human Use scientific report. +/– denotes yes or no binding/neutralization, respectively; n/a, data not available. This data
does not include semi-quantitation of the degree of binding/neutralization seen in Table 1A.
FIGURE 2 | Preclinical toxicity assessment of Quad-XTM tested in C57BL/6 mice. (A) The effect of treatment on the mean body weight of experimental mice. The
results shown are the means ± SEM (n = 10). Data was analyzed using an ANOVA multiple comparison test and Dunnett’s post analysis (p-value > 0.1 in all group
comparisons). (B) The effect of treatment on the mean organ to body weight ratio of experimental mice. Results shown are the means ± SEM (n = 10). Data was
analyzed using the non-parametric Kruskal–Wallis multiple comparison tests with a Dunn’s pair-wise test (p-value > 0.1 in all group comparisons vs. Vehicle treated
group).
week 3mean group body weight was 7.3± 0.4 g.When translated
into a human setting the effect of different doses on mean mouse
body weight has been shown to correlate with both a decrease
in joint pain levels and an increase in energy levels seen for
RA patients.
A lower incidence of histopathology lesions at week 10 was
observed in all Quad-XTM and D1-BA11-C4 treatment arms.
These outcomes were statistically differentiated from the 3-
week old control mice as well as the untreated (PBS treated)
mice. Evidence of cell infiltration, bone erosion and cartilage
degradation seen in 3-week-old and PBS-treatedmice groups was
present in 1 and 3 mg/kg Humira R© treated mice (Figure 5).
The standard dosing regimen utilized in this in vivo efficacy
study was based on the amount of drug in milligram per
body weight of animal in kilograms (mg/kg), therefore did
not correct for molecular size differences seen between formats
(Humira R©, 144 kDa, Quad-XTM, 105 kDa and D1-BA11-C4,
40 kDa). In previously published in vitro efficacy experiments,
an equimolar dosing regimen was adopted in an effort to
correct for molecular size differences, with the VNAR Quad-XTM
demonstrating 10x superior hTNF-α neutralizing potency when
compared to Humira R© (24).
DISCUSSION
About a decade ago, it was proposed that unlike VHH
domains, VNARs might not efficiently form dimeric fusion
molecules, and even where dimerization of VNAR was achieved,
the resulting dimeric construct was published as having
compromised expression levels and limited functional binding
activity; postulated to be the result of steric hindrance or
occlusion of the epitope by the incorporated linker (35, 37, 38).
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FIGURE 3 | Efficacy of Quad-XTM and D1-BA11-C4 in preventing arthritis in Tg197 mice. (A,B) Mean in vivo disease severity scores of all groups treated twice weekly
from week 3 of age. Results shown are the means ± SEM (n = 8). (C,D) Mean group arthritis histopathology scores at the end of the study (10 weeks of age).
Results shown are the means ± SEM (n = 8). (A,D) Data were analyzed using the non-parametric Kruskal-Wallis multiple comparison tests with a Dunn’s pair-wise
test. (A,B) (p-value < 0.0005 in all group comparisons vs. Vehicle treated group, except for Humira® 1 mg/kg vs. Vehicle, p = 0.92). (C,D) (p-value < 0.0005 in all
group comparisons vs. Vehicle treated group, except for Humira® 1 mg/kg vs. Vehicle, p = 0.1 and 3-week control group vs. Vehicle, p = 0.06).
FIGURE 4 | The effect of anti-hTNF-α treatment on the mean body weight of treated Tg197 mice. At the end of the study (10 weeks of age), the mean body weights
of all groups treated twice weekly from week 3 were determined, and end of study weight scores obtained. Results shown are the means ± SEM (n = 8). Data was
analyzed using an ANOVA multiple comparison test and Dunnett’s post analysis. (A) (p-value < 0.05 in all group comparisons vs. Vehicle treated group). (B) (p-value
< 0.05 in all group comparisons vs. Vehicle treated group except for Humira® 1 mg/kg vs. Vehicle, p = 0.77).
This speculation was later dismissed following the demonstration
that VNARs tolerate both N- and C-terminal molecular fusions
to form dimers and trimers without any obvious impact on
their inherent biophysical properties or expressibility (39). Since
these early reports, VNAR reformatting has become routine,
and rational, extensive reformatting can generate tailor-made
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FIGURE 5 | Representative histology images of ankle joints of treated Tg197 mice. Histology of inflammatory cell infiltration (green arrows), bone erosion (blue arrows),
pannus (yellow arrows), synovial hyperplasia (black arrows), and significant healing of arthritic joints in young Tg197 mice. Tissue sections of the ankle joints were
obtained from a 3-week-old baseline mouse grouping. In addition, tissue sections of the ankle joints were also obtained from a PBS treated vehicle control mouse
group, anti-hTNF-α Quad-XTM, D1-BA11-C4, and Humira® treated mouse groups at 10 weeks of age. Original magnification, 25x. (A) (From top, left to right:
3-week-control mice, vehicle (PBS) control mice, Humira® at 10 mg/kg; Bottom, left to right: Quad-XTM at 3, 10, and 30 mg/kg). (B) (From top, left to right:
3-week-control mice, vehicle (PBS) control mice, Humira® at 1 and 3 mg/kg; Bottom, left to right: Quad-XTM at 0.5, 1, and 3, D1-BA11-C4 at 30 mg/kg).
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constructs specifically designed for either systemic, site-specific
or topical delivery (24, 25, 40). These fusion constructs have been
expressed in E. coli, yeast and mammalian cells at scalable yields
and to the best of our knowledge, no evidence of significant
aggregation of these domains, even when concentrated up to 150
mg/ml with prolonged storage, has been reported. Extending the
half-life of therapeutic VNAR domains via molecular fusion is
now achievable with a molecular mass of drug candidates at 25
kDa (dimer) or 40 kDa (trimer) using NDureTM (39, 40) or 80–
100 kDa with an Fc fragment (24, 25). The benefits of smaller
and simpler biologic drug formats cannot be over-emphasized
and include: access to both extracellular and intracellular target
antigens, non-systemic alternative routes of administration,
reduced immunogenicity and cost/flexibility of production.
Although NDureTM fusion proteins and VNAR-Fc formats
had been previously administered systemically in several
preclinical proof-of-concept studies without in vivo toxicity
[non-human primate (26), rat—manuscript in preparation,
and mouse (25)], the Quad-XTM construct has never been in
vivo before. This first example of a quadra-valent VNAR has
demonstrated exceptional in vitro potency (2–5 picomolar) when
compared with conventional anti-TNF-α biologics in the clinic
(24, 41–43). In a preliminary MTD study in C57BL/6 mice, the
safety of the anti-TNF-α Quad-XTM at 30 mg/kg, administered
subcutaneously, was confirmed. There was no clinical evidence
of acute or delayed adverse events in these treated mice.
With its unique and protruding binding loops (CDR1 and
CDR3), we speculated that these anti-TNF-α domains (VNAR
D1 and C4), forming the backbone of the D1-BA11-C4 and D1-
Fc-C4 Quad-XTM constructs, may be interacting with unique and
previously unseen “recessed” epitopes on the TNF-α molecule,
in stark contrast to the epitopes recognized by the planar
paratopes of the commercially available biologics including even
VHH (35, 44–47). In a comprehensive TNF-α species cross-
reactivity characterization study, the lead anti-TNF-α VNARs
appeared to bind a unique TNF-α epitope. In addition, and using
data collected from the European Medicines Agency Evaluation
of Medicines for Human Use scientific report detailing other
commercially available TNF-α and TNFR1 antagonist biologics
(Tables 1A,B), whilst the binding/neutralization profile of our
VNAR domains share some similarity with Humira R© and
Simponi R©, these two biologics also bind/neutralize mouse and
rabbit TNF-α, respectively. In a BIAcoreTM epitope binning study,
a VNAR D1-C4 dimer and VHH TNF30-TNF30 recognized
different epitopes on immobilized human TNF-α (data not
shown). Although for cost effective drug development, it
is beneficial to demonstrate broad species cross-reactivity,
facilitating proof-of-concept preclinical studies in inexpensive
animal models, restricted cross-reactivity seems to be a feature of
improved human efficacy of TNF-α protein antagonist (32–34).
InTable 1, there is a striking and restricted cross-reactivity across
all listed clinical biologics. This restricted cross-reactivity is no
longer considered a limitation to the development of anti-TNF-α
biologics as the use of surrogate domains and transgenic animal
models of human disease (expressing human TNF-α) is now a
well-worn and successful clinical path (32, 48–50). In parallel
to the work published here, we have solved the structure of the
anti-TNF-α VNAR-human TNF-α complexes and the analysis of
this crystallization data has confirmed the binding of VNAR to a
novel epitope. Like Humira R© (47), one VNARmolecule interacts
with two adjacent TNF-α protomers. However, this is where the
similarity ends with only 10% of the TNF-α contact residues
common to both proteins (manuscript in preparation).
It is sometimes easy to forget that the original regulatory
and clinical path of anti-TNF biologics required the use of
surrogate binders in poorly predictive anti-inflammatory animal
models. This enforced strategy was adopted because molecules
such as Humirar (and here the Quad XTM) are unable to
bind and neutralize, with any therapeutically relevant potency,
rodent TNF-α. It is only with the recent development of new
transgenic disease models (27) that interrogation of a system that
approaches that seen in man is now possible. Although there
is strong evidence that models such as Tg197 mice are highly
predictive of future efficacy in man, these in vivo pre-clinical
data sets are typically less comprehensive than those generated
for other indications such as cancer, where the use of multiple,
related in vivomodels is often possible.
The development of TNF-α transgenic mice (Tg197) carrying
a 3’-modified UTR human TNF-α gene construct allows
deregulated soluble human TNF-α gene expression in vivo. These
mice develop chronic inflammatory polyarthritis resembling
human rheumatoid arthritis as early as 4 weeks after birth (27, 51,
52). It is clear that all types of RA and IBD in (human) patients
don’t begin with dysregulated TNF expression and certainly not
with the rapidity of the disease progression seen in Tg197 mice.
However, this model has proved to be an invaluable in vivo
tool capable of accurately forecasting the therapeutic potency
of anti-TNF drugs and accelerating the development of next-
generation anti-TNF-α biologic therapies. Where they have been
less informative is their ability to predict some of the now well-
recognized side effects that are associated with longer term anti-
TNF-α therapies such as increased susceptibility to opportunistic
infections, malignancies and cardiovascular risks (53–56). While
inflammatory disease in the Tg197 mouse model is solely driven
by soluble TNF-α, it is worth emphasizing that the soluble TNF-
α precursor, transmembrane TNF-α (tmTNF-α), is not only a
mediator of immunity but also displays anti-inflammatory and
anti-apoptotic reactions (57–59). Whilst establishing the tmTNF-
α binding and neutralizing profile of our VNARs may potentially
add value to our current knowledge, here it is the clinical
importance of targeting soluble TNF-α that has been the focus
of these studies, since it is binding and neutralization of the
soluble form of TNF-α that has been shown to be the critical
and common mechanism of action of all approved anti-TNF-α
therapeutic agents (60).
The in vivo efficacy of Quad-XTM and D1-BA11-C4 in a
Tg197 transgenic human TNF-α polyarthritis disease model
reinforces the validity of our previously reported potent in
vitro neutralization data which saw an order of magnitude
improvement over Humira R© (24). In this present study, clinical
efficacy seen with a 1 mg/kg dosing of Quad-XTM is slightly
better than, but comparable to, that observed with a 10
mg/kg Humira R© dose. In addition, breakthrough of underlying
disease was observed for both the 1 and 3 mg/kg Humira R©
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treatment regimens. It has previously been established that a
3 mg/kg Humira R© dosing is sub-therapeutic, at least in this
disease model (36). Although the Quad-XTM format clearly
demonstrated improved efficacy in this transgenic model over
Humira R©, it would be premature to make assumptions about
reducing any longer-term risks such as greater susceptibility to
infection in the absence of clinical data. The trimer construct D1-
BA11-C4 (40 kDa), is a second rationally designed therapeutic
format incorporating on this occasion an anti-HSA binding
domain, NDureTM (which cross-reacts with mouse serum
albumin) to extend serum half-life close to that of a wild
type immunoglobulin Fc region (39). The VNAR BA11 domain
located in the middle of the two anti-TNF-α also functions as
a spacer alongside the flexible 20 amino acid Gly4Ser linker
flanking both N- and C- terminals of BA11. The presence
of a spacer has previously been associated with a significant
enhancement in in vitro potency (24), and is an effect that has
been reported by other independent researchers (35, 61). This
relatively low molecular weight, super-potent trimer may also be
well-suited to topical and/or site-specific delivery in autoimmune
conditions such as IBD, uveitis, and psoriasis. A combination of
topical and site-specific delivery and the absence of an Fc region
is typically associated with reduced systemic toxicity (35, 62, 63),
further extends the format’s utility and compliance.
VNAR domains are evolutionarily distant from human and
other lower warm-blooded mammals, but evidence from both
in silico and dendritic cell-T-cell assays, capable of identifying
the presence or absence of potential T-cell epitopes, support
their inherent non-immunogenic features, at least in humans
(40), with an established route to humanization confirmed for a
number of VNAR domains (39). A humanized VNAR domain,
such as NDureTM, is often referred to in the literature as a
soloMERTM (24, 40, 64).
CONCLUSION
While dose escalation and in-class switching are approaches
utilized by clinicians to manage most anti-TNF-α biologics
non-responder patients, dose escalation eventually leads to
increased treatment cost, increased systemic toxicity, accelerated
immunogenicity, infusion reaction, and eventual termination of
therapy (13, 16, 65, 66). The anti-TNF-α Quad-XTM, which is
about two-thirds of the size of a conventional mAb, and the anti-
TNF-α NDureTM fusion product (40 kDa) both clearly have the
potential to be new and useful additions to the existing formulary
of anti-TNF biologics available to clinicians. Where these drug
candidates show real advantage as future disruptive therapies,
is through their enhanced in vivo potency and controlled
PK/delivery, predicting their use at significantly lower doses
than current standard of care biologics. It is hoped that this
tailoring of drug use will, in turn, limit the risk of anti-drug
antibodies, control/optimize the costs of drug therapy and begin
to reduce the systemic toxicity risks [infection and malignancies
(53–55, 67, 68)] seen from the practice of extended dose
escalation therapies.
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